Lisata Therapeutics

Focus: Lisata Therapeutics is a cell therapy biotechnology company focused on autologous and immunotherapy-based treatments for cardiovascular disease, cancer, and metabolic disorders. Founded in 2014 and headquartered in New Jersey, the company operates a diversified pipeline spanning Phase 1-3 development.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Lisata Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Lisata Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

Myocardial Ischemia

N/A

Clinical Trials (1)

NCT00545610ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

N/A

Help build intelligence for Lisata Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio depth: 17 active programs across cardiovascular, oncology, and metabolic indications with 2 Phase 3 programs offering clinical validation opportunities.
Emerging modality focus: Leading position in autologous cell therapy and dendritic cell immunotherapy, high-growth areas attracting institutional investment and partnerships.
Multiple clinical catalysts: Phase 3 readouts in chronic myocardial ischemia and melanoma immunotherapy provide near-term value inflection points.

Watch Out For

Zero current job openings and undisclosed employee count suggest minimal active hiring, indicating potential organizational constraints or funding limitations.
Pre-revenue stage with no disclosed funding or financial data creates cash-runway uncertainty and restructuring risk if Phase 3 programs encounter setbacks.

Generated by Claude from Lisata Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Biological/Vaccine: therapeutic autologous dendritic cells.

Kidney Cancer

Phase 1

Clinical Trials (1)

NCT00014131Vaccine Therapy in Treating Patients With Kidney Cancer

Phase 1

CLBS119

Covid-19

Phase 1

Clinical Trials (1)

NCT04522817CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

Phase 1

CEND-1

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT03517176CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Phase 1

CLBS201

Chronic Kidney Diseases

Phase 1

Clinical Trials (1)

NCT04990427CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Phase 1

certepetide

Pancreas Cancer

Phase 1/2

Clinical Trials (1)

NCT06592664Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Phase 1/2

therapeutic autologous dendritic cells

Melanoma (Skin)

Phase 1/2

Clinical Trials (1)

NCT00012064Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

Phase 1/2

CLBS12

Critical Limb Ischemia

Phase 2

Clinical Trials (1)

NCT02501018Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

Phase 2

CLBS03 Low Dose

Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT02691247Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

Phase 2

certepetide

Cholangiocarcinoma

Phase 2

Clinical Trials (1)

NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Phase 2

lymphokine-activated killer cells

Brain and Central Nervous System Tumors

Phase 2

Clinical Trials (1)

NCT00814593Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Phase 2

CLBS14

Myocardial Ischemia

Phase 2

Clinical Trials (1)

NCT00300053ACT34-CMI -- Adult Autologous CD34+ Cells

Phase 2

CLBS16

Coronary Microvascular Dysfunction

Phase 2

Clinical Trials (1)

NCT04614467A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Phase 2

NBS10

ST Segment Elevation Myocardial Infarction

Phase 2

Clinical Trials (1)

NCT01495364NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Phase 2

CLBS16

Coronary Microvascular Dysfunction

Phase 2

Clinical Trials (1)

NCT03508609Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Phase 2

Auto-CD34+ cells

Chronic Myocardial Ischemia

Phase 3

Clinical Trials (1)

NCT01508910Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Phase 3

Autologous Dendritic Cell-Tumor Cell Immunotherapy

Stage IV Melanoma

Phase 3

Clinical Trials (1)

NCT01875653Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Phase 3